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The X-Ray Structure of RANTES: Heparin-Derived
Disaccharides Allows the Rational Design
of Chemokine Inhibitors
subclass, is a highly basic, 68 amino acid protein, which
induces migration of T cells, monocytes, basophils, eo-
sinophils, natural killer cells, and dendritic cells (Baggio-
lini et al., 1997) by binding to several receptors, namely
CCR1, CCR3, and CCR5 (Rossi and Zlotnik, 2000). Over-
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14 Chemin des Aulx expression of RANTES has been associated with a vari-
ety of inflammatory disorders (Folkard et al., 1997; Rob-1228 Plan-les-Ouates
Geneva inson et al., 1995).
The immobilization of chemokines by interaction withSwitzerland
2 GeneProt proteoglycans on cell surfaces and the extracellular ma-
trix (Sweeney et al., 2002) is essential for their ability2 Rue du Pre´-de-la-Fontaine
1217 Meyrin to induce directional migration (Proudfoot et al., 2003).
In vitro, several chemokines have been shown to bindSwitzerland
3 Department of Protein Chemistry and Biophysics to glycosaminoglycans (GAGs), such as heparin, hepa-
rin sulfate, chondroitin sulfate, and dermatan sulfateInstitute of Pharmaceutical Chemistry
and Pharmaceutical Technology (Hoogewerf et al., 1997). In these in vitro studies, RANTES
displayed the widest range of affinities across the differ-University of Graz
A-8010 Graz ent GAGs and has a particularly high affinity for heparin
(Kuschert et al., 1999). Mutagenesis studies on RANTESAustria
have shown that the interaction of RANTES and heparin
is mediated principally through the highly basic BBXB
motif 44RKNR47, located on the 40s loop exposed onSummary
the surface of the protein (Proudfoot et al., 2001). The
RANTES-44AANA47 mutant still binds its CCR5 receptorThe biological activity of chemokines requires interac-
with wild-type affinity, but its affinity for its CCR1 istions with cell surface proteoglycans. We have deter-
decreased 200-fold (Proudfoot et al., 2001; Martin et al.,mined the structure of the chemokine RANTES (regu-
2001), demonstrating that the heparin binding sites can,lated on activation normal T cell expressed) in the
in some cases, overlap with the receptor binding site.presence of heparin-derived disaccharide analogs by
Certain chemokines, such as IL-8 (Rajarathnam et al.,X-ray crystallography. These structures confirm the
1994), MCP-1 (Paavola et al., 1998), MIP-1 (Laurenceessential role of the BBXB motif in the interaction be-
et al., 2000), and RANTES (Proudfoot et al., 2003), havetween the chemokine and the disaccharide. Unex-
been shown to achieve full receptor activation as mono-pected interactions were observed in the 30s loop and
mers, although they also form stable dimers. RANTESat the amino terminus. Mutant RANTES molecules
displays a marked propensity to oligomerize into higherwere designed to abrogate these interactions and their
order complexes at high concentrations, high pH, or inbiological activity examined in vivo. The K45E mutant
the presence of heparin (Czaplewski et al., 1999; Sturawithin the BBXB motif lost the capacity to bind heparin
et al., 2002). Mutants of RANTES, MCP-1, and MIP-1and the ability to elicit cellular recruitment. The Y3A
with either reduced affinity to heparin, or an abrogatedmutant maintained its capacity to bind heparin but
propensity to form dimers and higher-order oligomers,was unable to elicit cellular recruitment. Finally, a tet-
lose their in vivo capacity to recruit leukocytes despiterasaccharide is the smallest oligosaccharide which
being fully capable of binding their receptor in vitroeffectively abolishes the ability of RANTES to recruit
(Proudfoot et al., 2003).cells in vivo. These crystallographic structures provide
Recently, the glycosaminoglycan-cytokine interactiona description of the molecular interaction of a chemo-
has also become recognized as a therapeutic target inkine with glycosaminoglycans.
such applications as graft rejection (Fernandez-Botran
et al., 2002), and considerable efforts are now underwayIntroduction
to characterize the heparin binding domains of chemo-
kines (Koopmann et al., 1999; Chakravarty et al., 1998;The chemokine family is composed of approximately
Stringer and Gallagher, 1997; Stringer et al., 2002;40 members whose role is to direct cellular migration
Spillmann et al., 1998). Moreover, mutation of the GAGthrough interaction with receptors of the seven trans-
binding site of RANTES has revealed a novel anti-inflam-membrane G protein coupled receptor family. RANTES
matory strategy, since mutation of the basic residues(regulated on activation normal T cell expressed) (CC
in the BBXB heparin binding motif on the 40s loopchemokine ligand 5 [CCL5]), a member of the CC or 
(RANTES-44AANA47) has been shown to prevent cellular
recruitment by wild-type RANTES (Baltus et al., 2003),
*Correspondence: jeffrey.shaw@serono.com and furthermore, significantly reduces symptoms in a4 Current address: Celltech, 216 Bath Road, Slough, Berkshire SL1
murine model of inflammation, experimental autoim-4EN, United Kingdom.
mune encephalomyelitis (Johnson et al., 2004).5 Current address: Astex Technology, 436 Cambridge Science Park,
Milton Road, Cambridge CB4 0QA, United Kingdom. In order to more fully understand which residues in
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RANTES are directly implicated in binding to glycosa- duced by the action of heparin lyases that cleave heparin
between glucosamine residues and their downstreamminoglycans and to understand the structure of the
higher-order oligomerization states of RANTES in their uronic acids. These lyases produce disaccharides with
a nonnatural unsaturated 4,5-uronic acid at its nonre-presence, the cocrystallization of RANTES with gly-
cosaminoglycan-derived fragments was undertaken. ducing terminal. This unsubstituted uronic acid is thus
structurally different from the uronic acid present in theThe crystal structure of RANTES complexed to heparin-
derived disaccharides I-S and III-S were obtained. These heparin polysaccharide and care must therefore be
taken in the interpretation of the significance of the inter-structures confirmed the important role of the BBXB
motif in the 40s loop in binding to glycosaminoglycans, actions of this 4,5-uronic acid moiety with RANTES.
Cocrystallization of wild-type RANTES in presencebut identified several other unexpected interactions with
the 30s loop, and the N terminus. Residues within these of these heparin-derived disaccharides was attempted.
Crystals grew in all cases except in the presence ofregions which interacted with the disaccharides in the
crystal structure were mutated to residues which could heparin disaccharide I-A and IV-S (Table 1). The crystals
of RANTES grown in the presence of the heparin-derivednot maintain this interaction, and their in vivo activity
determined. disaccharides were all isomorphous to the wild-type
protein crystals. Unexpectedly, only disaccharides I-S
and III-S (which only differ by the presence of an
Results O-sulfate group at position C6 of the glucosamine moi-
ety of disaccharide I-S) were visible in the crystal struc-
Structure of Wild-Type RANTES ture, whereas heparin-derived disaccharides II-A and
and Heparin-Derived Disaccharides II-S (which lack the sulfate group on the C2 of the
The structure of wild-type RANTES and variants had glucuronic moiety) were not present in the crystals
previously been determined by both NMR (Skelton et grown in their presence.
al., 1995; Chung et al., 1995) and X-ray crystallography The overall structure of the RANTES molecule is unaf-
(Hoover et al., 2000; Wilken et al., 1999). In all cases the fected by the presence of the heparin-derived disaccha-
protein is a homodimer of monomers (hereafter called ride molecules, with the exception of the N terminus of
monomer A and monomer B) consisting of an NH2-termi- the B monomer of the RANTES dimer (Figure 2) in the
nal loop, three antiparallel  strands arranged in a Greek structure containing heparin-derived disaccharide I-S.
key motif, connected by loops, and a COOH-terminal  The rms deviation of the position of the main chain atoms
helix, which is the generic monomeric structure of all between residues 6 and 72 (excluding therefore the very
chemokines. The two crystallographic structures also mobile N-terminal region) of Met-RANTES and RANTES
contained several sulfate ions either near the BBXB loop containing heparin disaccharides I-S and III-S is 0.6 A˚
or near the dimer interface. Our assumption was that and 0.52 A˚, respectively. Residues 2–68 are visible for
the positions of these sulfate ions would reveal the bind- monomer A of both heparin-derived disaccharide I-S
ing site of the sulfate groups of heparan sulfate. Heparin and III-S containing crystals, whereas only residues 4–68
and heparan sulfate are long unbranched oligosaccha- are visible for both B monomers. There is a single hepa-
rides composed of variously sulfated disaccharide rin disaccharide I-S or III-S molecule in the asymmetric
building blocks (Figure 1). These disaccharide building unit, which contains a dimer of RANTES. The disaccha-
blocks are composed of a hexuronic acid moiety and a rides are nestled between three symmetry-related di-
D-glucosamine subunit linked by 1 → 4 linkages. The mers of RANTES and form either salt bridges or hydro-
uronic acid may either be -D-glucuronic acid or -L- gen bond interactions with all three (Figure 3). The
iduronic acid and can either be underivatised or 2-O- disaccharide interacts with residues at the N terminus
sulfated. The -D-glucosamine residue may be either of monomer A of the first RANTES dimer and with resi-
N-sulfated or N-acetylated. The N-sulfated glucos- dues of a solvent-exposed loop composed of residues
amines may also be O-sulfated at C3, C6, or both, or may Ser31A to Lys33A (hereafter called the 30s loop). This
not be O-sulfated at all. The N-acetylated glucosamines disaccharide also interacts with residues His23B,
may be O-sulfated at C6 or may be O-unsulfated. Thus Arg44B, and K45B (part of the 40s loop) of the B mono-
each disaccharide monomer has one of six possible mer of a second RANTES dimer, which is symmetry-
structures in the glucosamine position, and four possi- related to the first. A third, symmetry-related RANTES
ble structures in the glucuronic acid position. dimer, interacts with this disaccharide through residues
Since heparin is such a large polydisperse molecule, it Thr8B and Gly32B of the B monomer. The N termini
was concluded that initial studies should be undertaken and the 30s loops of both monomers are important for
with the much smaller, chemically well-characterized RANTES-disaccharide interaction, as well as the two
building blocks of the heparin polymer, such as sulfated residues of the BBXB motif previously identified as play-
D-glucosamines, hexuronic acids, and heparin-derived ing an important role in heparin binding (Proudfoot et
oligosaccharides. Since RANTES was found to precipi- al., 2001). The N terminus of the A monomer of RANTES
tate in the presence of heparin-derived fragments larger forms only one important hydrogen bond to the disac-
than a disaccharide and since these heparin-derived charide, through the OH of the side chain of Tyr3A.
disaccharides are readily available, are chemically pure, Probably as a consequence of this tight hydrogen bond,
and are chemically very similar to the smallest building the entire N-terminal main chain moves toward the hepa-
blocks of heparin molecules, they were chosen for this rin disaccharide, with the most movement occurring at
study. It should be noted, however, that the commer- the extreme end of the RANTES N terminus. The Tyr3A
side chain also undergoes an important change in posi-cially available heparin-derived disaccharides are pro-
Chemokine-Disaccharide Complexes
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Figure 1. Structure of Heparin
(A) Heparin polysaccharide structure.
(B) Heparin-derived disaccharide structure.
(C) Nomenclature of heparin disaccharides.
tion and swings around, with the OH group forming a the N terminus of the A-chain, despite the lack of any
hydrogen bond with the 2-sulfate group of the hexuro- direct interaction with the disaccharides. This N termi-
nic acid moiety of the disaccharide. This interaction is nus rotates around the Asp6B C-CO bond, with the
further stabilized by a hydrogen bond between the OH side chain pointing in the direction of the main chain in
group of Tyr3A and the O of Ser31A, an interaction the AOP and Met-RANTES structures. Residues 1–3 are
not observed in the AOP and Met-RANTES structures not visible in the electron density, and this movement
(Wilken et al., 1999; Hoover et al., 2000). The importance was only visible for residues 4–6. This movement was
of the interaction of the Tyr3 side chain with the heparin not observed in the structure containing heparin disac-
disaccharide prompted the preparation and character- charide III-S, and results in the lengthening of the
ization of the RANTES-Y3A mutant described below. The N-terminal  strand of the B chain by two amino acids
side chain of Ser4A apparently does not swing around (residues Ser4B and Ser5B). The new position of the
to interact with the disaccharide 2-SO4 group, despite Asp6B side chain also creates two new hydrogen bonds
being well within range to form a hydrogen bond with with the main chain N of Cys50A, which may play a role
the 2-SO4 group of the hexuronic moiety of the disac- in stabilizing the RANTES dimer upon binding of heparin.
charide. The side chain of Thr8A also swings around, Since none of residues 4B–6B bind directly to the hepa-
compared to AOP-RANTES or Met-RANTES structures, rin disaccharide, and there are no steric reasons for the
and forms two hydrogen bonds with two oxygen atoms movement of the N terminus, it is not entirely clear why
of the 2-SO4 group of the hexuronic acid. the movement should take place, unless it is simply due
The N terminus of the B-chain of the RANTES dimer to modified packing in the crystal lattice to allow the
undergoes a much more pronounced movement than presence of the disaccharide.
Several residues in the 30s loop form interactions ei-
ther with the disaccharides or within the protein moiety.
Table 1. Crystallization of RANTES with Different Heparin As mentioned above, the side chain of Ser31A forms
Disaccharides
a new hydrogen bond with the OH of Tyr3A, but this
Disaccharide Crystallization Concentration Visible interaction is not observed in the B monomer. The main
chain nitrogen of Gly32A forms a hydrogen bond interac-I-S Yes 1 mM Yes
tion with the 2-NH-SO4of the glucosamine moiety of theI-A Yes 1 mM or 10 mM No
II-S Yes 1 mM or 10 mM No disaccharide. The main chain nitrogen of a symmetry-
II-A No 1 mM or 10 mM No related Gly32B also forms a hydrogen bond interaction
III-S Yes 1 mM Yes
with this sulfate; this sulfate group of the disaccharide
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Figure 2. Structure of RANTES Dimers
Ribbon diagrams of dimers with space-filling
representation of small molecules in the crys-
tal lattice. Red regions in ribbon diagram cor-
respond to regions of the protein where the
position of the C- differs from that of the
AOP-RANTES structure by more than 2 A˚. A
monomers are colored in blue, and B mono-
mers in green. Side chains of residues inter-
acting with small molecules are shown.
(A) Dimer of AOP-RANTES with sulfate ions.
(B) Dimer of Met-RANTES with sulfate ions.
(C) Dimer of RANTES with heparin disaccha-
ride I-S.
(D) Dimer of RANTES with heparin disaccha-
ride III-S.
(E) Dimer of RANTES-K45E.
(F) Dimer of RANTES-44AANA47 with sulfate
ions.
is thus sandwiched between two Gly residues of the 30s A interact with the disaccharide, but several interactions
are observed with the BBXB motif of the B monomer.loop and thereby bridges two RANTES dimers. The K33A
side chain swings around substantially due to the move- The side chain of Arg44B is in an entirely new position,
compared to the AOP and Met-RANTES structures, andment of Tyr3A and unexpectedly points away from the
disaccharide. The Lys33B side chain also points away forms a salt bridge with the 6-SO4 group of the disac-
charide. This new position can be attributed to the vol-from the disaccharide, despite being sufficiently close
to interact with it. The fact that neither Lys33 side chain ume occupied by the disaccharide (formerly occupied
by the Arg44B side chain) and by the movement of theinteracts with the disaccharides is quite unexpected,
since salt bridge interactions would be possible. His23B side chain, which has pushed the Arg44B side
chain into its new position. One amino acid side chainNone of the residues of the BBXB motif of monomer
Chemokine-Disaccharide Complexes
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Figure 3. Stereo Diagrams of the Binding Site of Heparin Disaccharides in RANTES Crystals and Crystallographic Lattice
Heparin disaccharide and residues in close proximity are displayed. Carbon atoms colored in gray are from monomer A, those colored in
green or blue are from two different symmetry-related B monomers. Putative hydrogen bonds are shown in violet.
(A) Heparin disaccharide I-S with final 2Fo  Fc map contoured at 1.
(B) Heparin disaccharide III-S with final 2Fo  Fc contoured at 1.
(C) Crystal lattice of the complex between heparin disaccharide I-S and RANTES. Four dimers of RANTES are displayed.
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whose movement may result from the disaccharide ing direct contacts with a neighboring RANTES mole-
cule, through a strong hydrogen bonding between thebinding is His23B. The main chain near residue 23 under-
goes some movement, and the His side chain rotates guanidium group of Arg47B and both the O1 and the
main chain O of Glu66B of the neighboring RANTESalong its C-C bond to allow a salt bridge interaction
between the N	1 of the imidazol and a carboxylate oxy- molecule (this residue had already been implicated in
RANTES oligomerization [Czaplewski et al., 1999]).gen of the uronic acid of the disaccharide.
The Lys45B side chain interacts with several atoms of Thus, only Arg47 in the BBXB motif is implicated in
interactions with neighboring molecules, and its ab-the disaccharide. Two weak hydrogen bonds are formed
between the N and two oxygens of the 6-SO4 of the sence is probably responsible for the change is crystal
packing in the RANTES-44AANA47 mutant crystals.glucosamine. These interactions are not present in the
RANTES-heparin disaccharide III-S structure due to The structure of the RANTES-44AANA47 mutant is oth-
erwise essentially unaffected by the mutations. The rmsthe lack of the 6-SO4 group. The N of Lys45B also forms
a salt bridge with the carboxylate group of the uronic deviation of the position of the main chain atoms of the
residues 6–68 of RANTES-44AANA47 mutant comparedacid moiety. While this interaction is conserved in the
RANTES-heparin disaccharide III-S, this interaction with those of Met-RANTES is only 1.14 A˚ for the first
dimer and 0.99 A˚ for the second. The region of themust be examined with care, due to the non-natural
presence of the 4,5 double bond. mutations in monomer A was poorly defined, and resi-
dues Ala44A and Ala45A were not visible in the electron
density. The modeling of this region was further compli-
Structure of RANTES- 44AANA47 and Heparin cated by the presence of a sulfate ion in the 40s pocket
Disaccharides described above. The 40s loop of the B monomer is well
The crystallization of the RANTES-44AANA47 mutant was defined and essentially identical to that of wild-type
attempted in the presence of heparin disaccharides RANTES, as was the case for monomers C and D. The
with the hope that removal of this primary disaccharide most important movement caused by the mutations oc-
binding domain would permit the binding of a heparin- curs in the 20s loop, probably due to the fact that the
derived disaccharide to another part of the RANTES His23 side chain no longer interacts with residues in the
molecule, thereby permitting a mapping of the binding 40s pocket.
region of long chain heparin molecules by sequential
mutagenesis. All efforts to produce crystals of this mu-
tant in the presence of heparin disaccharides have Structure of RANTES-K45E
The analysis of the structure of RANTES in the presenceproven vain, but the protein did crystallize in the pres-
ence of 200 mM (NH4)2SO4. Three sulfate ions were ob- of heparin disaccharides suggested a new mutation,
which should mimic the results obtained with theserved, two binding to monomer A and one to monomer
C (Figure 4F). The first sulfate ion in monomer A binds RANTES-44AANA47, but which would involve a single
amino acid substitution. In this case, Lys45 was mutatedto the main chain nitrogens of residues Lys56A and
Trp57A, but does not interact with the side chains of to a glutamate residue, producing a charge reversal in
the middle of the BBXB motif. The glutamate side chainLys55A or Lys56A. This sulfate ion also interacts with the
side chains of residues of the 50s loop of a symmetry- was expected to prevent the interactions seen between
the wild-type RANTES and the heparin disaccharidesrelated RANTES monomer B, with hydrogen bonds to
Lys56B and Arg59B. The second sulfate ion binds in the by sequestering the neighboring Arg44, His23, and
Arg47 side chains through salt bridge or hydrogen bond-40s pocket in a position similar to that of the sulfate ion
observed in the AOP-RANTES structure, and interacts ing interactions. This protein was crystallized in the pres-
ence of heparin disaccharide I-S, and crystallized in thewith the side chains of His23 and Thr43. The sulfate ion
in monomer C forms the same interactions with the main same space group as the wild-type protein, but the unit
cell dimensions were substantially different (Table 2).chain nitrogens, but also forms a hydrogen bond with the
side chain of Lys55C. The interactions with a symmetry- The overall structure of the protein was unaffected by
the mutation, with the exception of the N termini of bothrelated monomer D 50s pocket are also maintained.
These specific interactions with residues of the 50s re- monomers, which adopted a configuration similar to that
of the B monomer of RANTES in the presence of heparingions may reveal a putative secondary heparin binding
site. disaccharide I-S. The 40s loop of RANTES-K45E also
underwent some minor movement of the main chain.This mutant protein produced crystals with greatly
modified packing, apparently due to the role played by Unsurprisingly, there was no trace of the heparin disac-
charide in the crystal structure. This absence is probablythe mutated residues in this packing (data not shown),
with two dimers of RANTES in the asymmetric unit, re- due to the reduced affinity of the mutant protein for
heparin oligosaccharides and to the new crystallo-lated by a noncrystallographic 2-fold symmetry axis
roughly parallel to the a axis (data not shown). In the graphic packing, which essentially precludes the pres-
ence of the disaccharide molecule near the 40s loop,case of wild-type RANTES, the only amino acid of the
BBXB motif in the A monomer of the mutant protein due to interactions of the latter with neighboring protein
molecules.that forms important interactions with symmetry-related
RANTES molecules is Arg47A, whose side chain forms The mutated Glu45 side chain does form some inter-
esting interactions with the neighboring basic sidean important hydrogen bond with the main chain O of
Ser65A of a neighboring RANTES molecule. The situa- chains. In the case of the A monomer, the side chain of
Glu45A swings toward the interior of the 40s pocket andtion is similar in the B monomer, with only Arg47B form-
Chemokine-Disaccharide Complexes
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Figure 4. Structure of RANTES Mutants
The carbon atoms of mutated residues are shown in yellow.
(A) Structure of the 40s loop of AOP-RANTES.
(B) Structure of the 40s loop of monomer A of RANTES-K45E.
(C) Structure of the 40s loop of monomer B of RANTES-K45E.
(D) Structure of the 40s loop of monomer C of RANTES-44AANA47.
(E) Structure of 40s loop of monomer D of RANTES-44AANA47.
(F) Structure of RANTES-44AANA47 near the sulfate ion binding to the 50s loop. Final 2Fo-Fc contoured at 1.
the carboxylate group forms two hydrogen bond/salt carboxylate group interacting with the N of His23A (Fig-
ure 4B). This interaction moves the 20s loop substan-bridge interactions, one with the O of the side chain
of Thr43A and one with probably both oxygens of the tially closer to the 40s loop than in the wild-type struc-
Structure
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Table 2. Crystallographic Data on RANTES-Heparin Disaccharide Complexes or Mutants
HD I-S HD-IIIS RANTES-44AANA47 RANTES-K45E
Space group P212121 P212121 P21 P212121
a 24.01 24.07 22.82 29.69
b 56.29 56.42 80.48 58.49
c 94.41 95.35 65.44 72.12
 94.52
Data Collection
Resolution range (A˚) 20.0–2.0 20.0–2.0 20.0–2.2 20.0–1.7
Total observations 38,679 64,883 32,702 67,032
Independent reflections 9,099 10,362 11,304 13,261
Completeness (%)1 98.8 (98.7) 96.0 (90.9) 93.9 (75.0) 91.7 (88.2)
Rmerge (%)a,b 6.5 (19.1) 4.0 (14.9) 8.7 (26.6) 4.6 (8.0)
I/1 20.3 (6.8) 31.5 (9.5) 11.3 (2.9) 28.9 (18.9)
Refinement
Resolution range 20.0–2.0 20.0–2.0 20.0–2.2 20.0–1.7
Reflections 
 0.0 9,067 8,929 11,269 13,221
Rfactorc 19.8 20.0 22.2 20.6
Rfree (5% of data)d 25.5 25.2 30.6 25.4
Rms deviations
Bond lengths (A˚) 0.005 0.005 0.006 0.004
Bond angles () 1.3 1.3 1.3 1.3
Number of atoms
Protein 1030 1037 2020 1059
Disaccharide 35 31 — —
Water 159 150 193 310
Other 4 4 15 4
Average B factor 18.2
Protein 21.7 19.9 20.1 14.3
Disaccharide 36.4 35.5 — —
Water 35.4 32.0 25.8 31.0
a Numbers in parentheses refer to the highest resolution shell.
b Rmerge  hkli|I  I
|/hkli I
, where I  observed density.
c Rfactor  hkl[|Fobs|  |Fcalc|]/hkl|Fobs|.
d Rfree is the Rfactor for 5% of the reflections excluded from the refinement.
ture. Contrary to our predictions, the Glu45A does not 44AANA47, which showed a 100-fold drop in potency while
achieving full efficacy, displayed wild-type activity in aninteract with either Arg44 or Arg47. In the B monomer,
the side chain of Glu45A points away from the 40s in vitro chemotaxis assay (data not shown). The capacity
of these mutant RANTES molecules to recruit leukocytespocket toward the solvent, and the carboxylate group
interacts only with solvent (Figure 4C). in a peritoneal recruitment assay was then measured in
order to determine whether the mutants had conserved
their biological activity. As shown in Figures 5B andBiological Activity of RANTES Mutants
with Impaired Heparin Binding 6C, both the RANTES-K45E and RANTES-Y3A have lost
their capacity to recruit cells, as is the case for theThe analysis of the structure of the complex between
RANTES and heparin disaccharides also prompted the RANTES-44AANA47 mutant (Proudfoot et al., 2003),
thereby confirming the biological importance of the rolepreparation of the RANTES mutant Y3A, since, in the
crystal structure, this residue interacts strongly with of Tyr3. Moreover, as we have previously observed for
RANTES-44AANA47, these mutants were able to inhibitheparin disaccharides. While the structure of this
RANTES mutant could not been determined, due to diffi- the ability of RANTES to recruit cells in vivo (Johnson
et al., 2004).culties in obtaining crystals both in the presence and
absence of disaccharides, its affinity for a heparin-
derived octasaccharide was determined by isothermal Affinity of Heparin and Heparin-Derived
Saccharides to RANTESfluorescence titration, as was that of the other RANTES
mutants, RANTES-44AANA47 and RANTES-K45E. While A study of the relative affinity of RANTES toward hepa-
rin-derived disaccharides and heparin molecules wasboth RANTES-44AANA47 and RANTES-K45E display a
greatly reduced affinity toward heparin, the RANTES- also undertaken by competition equilibrium experiments
on immobilized heparin beads using fractionated hepa-Y3A mutant maintained a surprising wild-type affinity
toward the heparin octasaccharide (Figure 5A). This sug- rin oligosaccharides ranging in size from disaccharides
to 18mers and a commercially available LMW heparingests that the strong interaction observed between the
Tyr3A side chain and the heparin disaccharide mole- preparation. These studies were also performed against
RANTES receptors, CCR1 and CCR5 to determine whethercules may either be due to the tight packing in the crystal
lattice or may be entirely fortuitous. oligosaccharides could compete with the receptors for
RANTES binding. Heparin-derived disaccharides wereBoth of these mutants displayed wild-type affinity to-
ward their receptor CCR5 and, contrary to RANTES- very inefficient in competing for RANTES, requiring milli-
Chemokine-Disaccharide Complexes
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Figure 5. Biochemical Characterization and
In Vivo Behavior of RANTES Mutants
(A) Relative affinity of mutant and wild-type
RANTES for heparin octasaccharide. Black
squares, wild-type RANTES; inverted white
triangles, RANTES-44AANA47; black triangles,
RANTES-K45E; and white triangles, RANTES-
Y3A for a heparin octasaccharide as mea-
sured by isothermal fluorescence titrations.
(B) Inhibition by RANTES-Y3A of peritoneal
cellular recruitment induced by RANTES. Ten
micrograms of RANTES-Y3A is unable to in-
duce peritoneal recruitment (light gray bar).
The peritoneal cell recruitment induced by 10
g of RANTES can be inhibited by RANTES-
Y3A in a dose-dependant manner (gray bars).
(C) Inhibition by RANTES-K45E of peritoneal
cellular recruitment induced by RANTES. In
a similar manner, RANTES-K45E (light gray
bars) is unable to induce peritoneal cell re-
cruitment. The peritoneal cell recruitment in-
duced by RANTES (black bar) is also inhibited
in a dose-dependent manner by RANTES-
K45E (gray bars).
molar concentrations, with the exception of CCR1 where of 210, 53, and 304 M for CCR1, CCR5 and heparin,
respectively. The affinities increase with increasingit had an IC50 value of 366 M (Table 3). The higher
affinity of the disaccharides for CCR1 could be explained chain length (Table 3), where the 18-mer, displays an
IC50 value of 1.45 M toward CCR1, 0.6 M for CCR5,by the fact that the residues in the heparin binding BBXB
motif are also involved in CCR1 binding. However, the and 2.4 M for heparin, similar to results recently re-
ported (Vives et al., 2002). These results suggest thataffinity increases considerably as the heparin chain
length increases, since a tetrasaccharide had an IC50 only heparin molecules long enough to occupy more
than one pocket in the 40s loop can compete RANTES
off the heparin beads. Another hypothesis is that
RANTES, when bound to heparin beads, forms a higher
order oligomer state, with interactions not only between
RANTES and heparin, but also between neighboring
RANTES molecules, and the heparin-derived disaccha-
rides are incapable of disrupting this oligomerization
Table 3. The IC50 Values Obtained or Heparin and Heparin-
Derived Oligosaccharides by Competition Equilibrium
Binding Assays
Number of
Saccharides CCR1 CCR5 Heparin
2 366.00 
1000 
1000
4 210.00 53.00 304.00
6 91.00 44.60 196.00
8 43.00 5.83 18.40
10 5.00 3.54 25.50
Figure 6. Inhibition of Peritoneal Cellular Recruitment Induced by 12 4.00 1.67 9.20
RANTES by Heparin-Derived Oligosaccharides 14 1.80 0.95 4.60
16 1.03 0.74 6.00The peritoneal cell recruitment induced by 10 g of RANTES (black
18 1.45 0.62 2.40bar) can be inhibited by pretreatment, 30 min prior to RANTES
Heparina 0.06 0.18 2.37injection, by injection of 20g of heparin (stippled bar). Pretreatment
with a heparin-derived disaccharide at a 15-fold molar excess, com- IC50 values given in M.pared to the injected RANTES, has no effect on RANTES-mediated a An average mass of 17.5 kDa was used to calculate the IC50 valuecell recruitment. The inhibitory effect of pretreatment with heparin- for the commercially available heparin preparation, which contains
derived tetra-, hexa- and octasaccharides depends on the molar heparin with mass between 5 and 30 kDa.
excess of oligosaccharides.
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state, contrary to longer heparin molecules. In fact, it is This is consistent with the estimated binding constants
measured by protein NMR using diffusion filters (resultslikely that both these phenomena play a role (see below).
The affinity of the fractionated heparin to inhibit not shown) at low pH and using native as well as the
two nonaggregating RANTES mutants, which clearly in-RANTES activity was analyzed using the peritoneal cel-
lular recruitment assay in vivo. The purified heparin dicated that an N-acetylated heparin disaccharide had
a poorer Kd that the N-sulfated equivalent. It is thus alsopreparation is able to completely abrogate RANTES in-
duced recruitment at a dose of 20 g (Figure 6), and likely that formation of a crystallographic lattice requires
the presence of this sulfate group.the effect is dose dependent (Johnson et al., 2004). A 15-
fold excess of heparin tetrasaccharide, hexasaccharide, Surprisingly, the position of the two sulfate ions in the
BBXB pocket of the AOP-RANTES and Met-RANTESand octasaccharide were also able to fully inhibit
RANTES activity in vivo, while the disaccharide was in- does not correspond to the position of any of the sulfates
in the disaccharide structures. These sulfate ions thusactive (Figure 6). The inhibition is dose dependent, since
a 3-fold excess of tetrasaccharides did not result in did not correctly predict the positions of the sulfate
groups of the disaccharides. However, the position ofstatistically significant inhibition (contrary to longer oli-
gosaccharides), whereas a 15-fold excess did. Thus the the NH-SO4 of the glucosamine in the RANTES-disac-
charide structures corresponds to the sulfate ion bind-results obtained in the in vitro assays were confirmed
in vivo, demonstrating that the minimal repeating disac- ing to the Ser31A side chain identified in both previously
described crystallographic structures. However, the in-charide unit is insufficient to inhibit RANTES activity,
but molecules such as tetra-, hexa- or octasaccharides teraction of this NH-SO4 with the O of Ser31 appears
much weaker, since the new main interaction of theare efficient inhibitors.
Ser31A side chain is with the OH of Tyr3A.
While crystals of RANTES-44AANA47 in the presence
Discussion of heparin disaccharides could not be obtained, the
structure of the protein revealed the presence of three
All chemokines studied to date bind heparin in vitro. sulfate ions. One of these sulfate ions binds in the 40s
While this binding is probably due to charge interactions pocket of monomer A in a manner similar to that ob-
between the generally positively charged chemokines served in the AOP-RANTES and Met-RANTES, albeit
toward the very negatively charged heparin molecules, with some important differences probably due to the
or other members of the GAG family, the specificity of presence of the three mutated residues. The two new
this interaction is demonstrated by the fact that the two sulfate ions not previously observed in a RANTES crystal
acidic chemokines MIP-1 and MIP-1 do bind heparin, both bind to the main chain nitrogens of Arg56A and
albeit rather weakly (Koopmann and Krangel, 1997; Arg57A, in monomers A and C in what had already been
Koopmann et al., 1999). It is believed that binding of suspected as being a secondary heparin binding site
chemokines to GAGs is necessary for the development (Burns et al., 1998). Initial results had indicated that the
of a chemokine gradient, in order to elicit the recruitment RANTES mutant RANTES-55AAWVA59 displays normal
of leukocytes from the circulation, and we have recently heparin binding in vitro (Proudfoot et al., 2001). These
formally demonstrated the importance of this interaction results do not necessarily preclude the role of this region
for the biological activity of three chemokines in vivo as a secondary weak heparin binding site, since isother-
(Proudfoot et al., 2003). mal titration studies have identified a small decrease in
The rapid precipitation of the RANTES protein ob- the Kd of this RANTES mutant toward heparin (A.K.,
served after the addition of many disaccharides sug- unpublished data).
gests that these disaccharides promote rapid oligomer- Preliminary results on the crystallization of RANTES
ization, similar to what had previously been reported for suggest that conditions that favor oligomerization of
longer chain heparins (Stura et al., 2002; Koopmann and RANTES also favor its crystallization. For example, the
Krangel, 1997; Wagner et al., 1998). The lack of success mutants E66S/A and E26A, which form dimers and tetra-
in obtaining crystals with both purified heparin-derived mers respectively, but which cannot form higher order
tetrasaccharides and hexasaccharides in our hands can oligomers (Nichols et al., 2000), do not crystallize. The
probably be attributed to the same reason. We are cur- heavy precipitate observed upon addition of various
rently performing crystallization trials on a panel of che- heparin-derived oligosaccharides to RANTES might be
mokine mutants that have lost their propensity to oligo- the result of extensive oligomerization. The molecular
merize. mass of a RANTES-heparin disaccharide complex ex-
The fact that certain disaccharides were either not ceeds 600 kDa (in which RANTES has a molecular mass
visible in the crystal structure or did not permit crystalli- of 8 kDa, and the disaccharide a mass of approximately
zation reveals some of the features that RANTES re- 600 Da), as determined by size exclusion chromatogra-
quires of the disaccharides, and by extension, to larger phy (results not shown) in conditions very similar to
heparin molecules. For example, sulfation at the 6-OH those used for the crystallization of the complex. Extrap-
of glucosamine is not absolutely required, since the hep- olation of this line of reasoning leads to the possibility
arin disaccharide III-S, which lacks this sulfate, was not that the crystal lattice reflects this natural oligomer state
only capable of crystallizing, but was also visible in the of RANTES.
crystal lattice. On the other hand, the NH-SO4 sulfate In the crystallographic lattice, 5860A2 of the RANTES
group appears to be much more important, since the dimer are buried, of the 7740A2 of total surface area,
N-acetylated disaccharides either did not crystallize (HD which corresponds to 76%. Of the 84 amino acids of
symmetry-related RANTES molecules in contact withII-A) or were not visible in the crystal lattice (HD I-A).
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the RANTES dimer, only three form salt bridges involving of the N terminus region in heparin-induced oligomeriza-
tion remains to be demonstrated experimentally.their side chains. Two of these salt bridges involve the
side chains of Arg47B and Glu66B, and Asp6A and The crystallographic structure of RANTES with hepa-
rin disaccharides has provided, to our knowledge, theLys25B, respectively, and are maintained in the heparin
disaccharide crystal structure. In the case of the first structural information concerning this essential in-
teraction and suggests several ways in which this inter-RANTES-disaccharide structures, the important move-
ment of the N terminus of the B monomer disrupts the action may play a role in RANTES activity. Moreover,
examination of the structure allowed the prediction ofinteraction of Glu66A with the Ser5 side chain observed
in the Met-RANTES and AOP-RANTES structures. The two mutants, which proved to have the same inhibitory
properties of the triple mutant in which the basic resi-interaction of the Glu66B with the Arg47A of a neigh-
boring RANTES dimer is maintained. We initially be- dues in the BBXB motif were replaced with neutral Ala
residues. In the first case, a single charge reversal muta-lieved that the Glu66 side chain might therefore play a
similar role in both RANTES oligomerization and tion of Lys45 was found to be sufficient to result in these
inhibitory properties, whereas the second and unex-RANTES crystallization. However, the new crystal lat-
tice, revealed in the structure of the RANTES-44AANA47, pected mutation at Tyr3 did not impair heparin binding.
Whether this residue is involved in heparin induced oli-suggests that it is Arg47 that is essential for RANTES
oligomerization. In the structure of this mutant, the gomerization remains to be elucidated. The reason why
a heparin-derived tetrasaccharide is capable of fully ab-Glu66A and Glu66C side chain forms a new hydrogen
bond with a neighboring molecule, but through the N2 rogating the chemotactic response, while a disaccha-
ride is not, is currently being studied. A precise under-of His23A. This interaction was not present in the wild-
type structures, since this His side chain was interacting standing of the molecular basis of these interactions
may permit the design of molecules that disrupt theeither with sulfate ions, or heparin disaccharides.
Glu66B does not form any interaction with neighboring interaction, as demonstrated by the efficacy of a tetra-
saccharide in vivo, which could be of use in modulatingmolecules, and Glu66D forms a new hydrogen bond with
the N of a symmetry-related Lys55. It is likely that the various inflammatory diseases.
interaction between Glu66 and neighboring molecules
is not specific, and that a negatively charged side chain Experimental Procedures
will always find a positively charged partner in such a
Mutagenesis and Protein Purificationpositively charged molecule such as RANTES. The case
The RANTES mutants RANTES-E26A, Met-RANTES-E66S, RANTES-for the role of Arg47 in oligomerization is stronger than
44AANA47, RANTES-Y3A, and RANTES-K45E, were created by PCRthat of Glu66, since in all RANTES structures obtained
site-directed mutagenesis using a technique based on two mutant
so far, this Arg47 always interacts with neighboring primers and two terminal primers. Wild-type and mutant proteins
RANTES molecules. were purified as described (Proudfoot and Borlat, 2002). Heparin and
The role of heparin binding and oligomerization of heparin-derived disaccharides were purchased either from Sigma
or from Dextra Laboratories. Heparin oligosaccharides were alsoRANTES has also been studied by Biacore, by observing
obtained from Iduron, Manchester UK.the effect of heparin oligosaccharides on a mutant
RANTES, lacking residues 1–8, and therefore incapable
of dimerizing (Vives et al., 2002). In this study, oligomeri- Crystallography
RANTES at 10 mg/ml in 50 mM acetate buffer (pH 3.5) containing thezation of RANTES could only be caused by the presence
heparin-derived disaccharides (Table 1) at concentrations varyingof heparin. The binding of RANTES to heparin was ob-
between 0.5 and 10 mM was crystallized at room temperature byserved to implicate two phenomena; oligomerization
hanging drop vapor diffusion. Five microliters of RANTES were
along the GAG chain and positive cooperativity (i.e., mixed with 5 l of 15% (w/v) PEG 400, 100 mM acetate buffer (pH
interaction between RANTES molecules). It is probable 4.5), and 10% (w/v) glycerol. Crystals grew over a period of days
as thick needles to dimensions of 0.2  0.05  0.05 mm. Prior tothat several RANTES molecules bind to one heparin
freezing directly in the cryostream, crystals were transferred to achain by interacting not only with the oligosaccharides,
cryosolvent solution containing 25% (w/v) PEG 400, 100 mM acetatebut also among themselves. These results are consis-
buffer (pH 4.5), and 10% glycerol and the disaccharide. Crystallo-tent with the results presented here.
graphic data was collected at 100 K on an Enraf-Nonius FR591
It is likely that the binding between heparin and rotating anode generator equipped with Osmic MaxFlux mirrors and
RANTES covers a much larger surface than that ob- a MAR345 image plate detector. All crystals of wild-type RANTES
served by the disaccharide structure. This might explain belong to orthorhombic space group P212121 with unit cell dimen-
sions a  24 A˚, b  56 A˚, c  94 A˚. Crystals of the mutant RANTES-why disaccharides are incapable of efficiently compet-
44AANA47 were obtained in the same conditions as the wild-typeing for RANTES binding to either its receptors or to
protein, i.e., 25% PEG 400, 100 mM acetate buffer (pH 4.5), 200 mMimmobilized heparin, or inhibit its activity in vivo, despite
(NH4)2SO4, and 10% (v/v) glycerol, but belong to space group P21affinity constants in the micromolar range, while heparin, with unit cell dimensions a  22.8 A˚, b  80.5 A˚, c  65.4 A˚, with
or fragments as small as tetrasaccharides, are able to   94.5. RANTES-K45E crystallized in 20% PEG 400 and 100 mM
prevent cellular recruitment induced by RANTES into acetate buffer (pH 4.5), but in the absence of (NH4)2SO4, and the
crystals belonged to space group P212121, as the wild-type proteinthe peritoneal cavity. The identification of an important
crystals, but with different unit cell dimensions: a  29.7 A˚, b interaction between the disaccharide and the residue
58.5 A˚, c  72.1 A˚. The wild-type protein crystals contain a dimerTyr3 at the N terminus, confirmed by mutagenesis as
in the asymmetric unit, as did the RANTES-K45E crystals, whereasbeing important for biological activity in vivo, although
the RANTES-44AANA47 protein crystals contained two dimers in the
the heparin binding was unaltered, would suggest an asymmetric unit. Data was processed using DENZO and SCALE-
important level of cooperativity between GAG binding PACK (Otwinowski and Minor, 1997). Rigid body, simulating anneal-
ing, positional and B factor refinement were performed with CNSand the formation of higher-order complexes. The role
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(Brunger et al., 1998) and model building with O (Jones et al., 1991). G., Crespo, F.A., Oliver, R., Orhun, H.I., Quan, E.E., Maldonado, C.,
et al. (2002). Targeting of glycosaminoglycan-cytokine interactionsBulk solvent and anisotropic B factor corrections were applied.
as a novel therapeutic approach in allotransplantation. Transplanta-
tion 74, 623–629.Competition Equilibrium Binding Assays
The affinity of RANTES and its mutants for heparin and heparin- Folkard, S.G., Westwick, J., and Millar, A.B. (1997). Production of
derived oligosaccharides was assessed by the ability of the saccha- interleukin-8, RANTES and MCP-1 in intrinsic and extrinsic asthma-
rides to displace iodinated RANTES from immobilized heparin beads tics. Eur. Respir. J. 10, 2097–2104.
according to (Kuschert et al., 1999). The affinity for CCR1 and CCR5
Goger, B., Halden, Y., Rek, A., Mosl, R., Pye, D., Gallagher, J., and
was measured by their ability to displace iodinated RANTES from
Kungl, A.J. (2002). Different affinities of glycosaminoglycan oligo-
CHO membranes expressing recombinant receptor using a scintilla-
saccharides for monomeric and dimeric interleukin-8: a model for
tion proximity assay (Alouani, 2000).
chemokine regulation at inflammatory sites. Biochemistry 41, 1640–
1646.
Isothermal Fluorescence Titrations
Hoogewerf, A.J., Kuschert, G.S., Proudfoot, A.E., Borlat, F., Clark-Steady state fluorescence measurements were performed on a Per-
Lewis, I., Power, C.A., and Wells, T.N. (1997). Glycosaminoglycanskin Elmer (Baconsfield, UK) LS50B fluorimeter according to Falsone
mediate cell surface oligomerization of chemokines. Biochemistryet al. (2002) and Goger et al. (2002).
36, 13570–13578.
Hoover, D., Shaw, J.P., Gryczynski, Z., Proudfoot, A.E., and Wells,Peritoneal Cell Recruitment
T.N. (2000). The crystal structure of Met-RANTES: Comparison withPeritoneal cell recruitment was performed essentially as described
native RANTES and AOP-RANTES. Protein Pept. Lett. 7, 200.in Johnson et al. (2004).
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